PHN Stock Overview
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for PHN from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Pharmanutra S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €53.20 |
| 52 Week High | €63.50 |
| 52 Week Low | €44.85 |
| Beta | 0.33 |
| 1 Month Change | -4.14% |
| 3 Month Change | -9.52% |
| 1 Year Change | -4.66% |
| 3 Year Change | -26.92% |
| 5 Year Change | 129.31% |
| Change since IPO | 280.27% |
Recent News & Updates
Recent updates
Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings
Sep 11
Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 23Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?
Sep 26These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely
May 16Pharmanutra (BIT:PHN) Could Easily Take On More Debt
Jan 11Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal
Nov 02Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around
Aug 03Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?
May 20Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)
Apr 19Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?
Mar 10Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?
Feb 17
Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?
Feb 01Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?
Jan 18Is Pharmanutra (BIT:PHN) A Risky Investment?
Jan 04Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return
Dec 22Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?
Dec 08Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 23Shareholder Returns
| PHN | IT Personal Products | IT Market | |
|---|---|---|---|
| 7D | -1.7% | 0.6% | -0.4% |
| 1Y | -4.7% | -5.9% | 10.8% |
Return vs Industry: PHN exceeded the Italian Personal Products industry which returned -5.9% over the past year.
Return vs Market: PHN underperformed the Italian Market which returned 10.8% over the past year.
Price Volatility
| PHN volatility | |
|---|---|
| PHN Average Weekly Movement | 3.2% |
| Personal Products Industry Average Movement | 3.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.7% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: PHN has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: PHN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 119 | Roberto Lacorte | www.pharmanutra.it |
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.
Pharmanutra S.p.A. Fundamentals Summary
| PHN fundamental statistics | |
|---|---|
| Market cap | €518.83m |
| Earnings (TTM) | €16.27m |
| Revenue (TTM) | €113.13m |
31.4x
P/E Ratio4.5x
P/S RatioIs PHN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHN income statement (TTM) | |
|---|---|
| Revenue | €113.13m |
| Cost of Revenue | €56.03m |
| Gross Profit | €57.09m |
| Other Expenses | €40.82m |
| Earnings | €16.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 14, 2025
| Earnings per share (EPS) | 1.69 |
| Gross Margin | 50.47% |
| Net Profit Margin | 14.38% |
| Debt/Equity Ratio | 39.6% |
How did PHN perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 20:48 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmanutra S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrea Randone | Intermonte SIM S.p.A. |
| Giorgio Tavolini | Intermonte SIM S.p.A. |
| Daniele Alibrandi | Stifel, Equities Research |